Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.

ABSTRACT:

Aims

This study surveyed individuals and caregivers of children who received teplizumab at stage 2 type 1 diabetes (T1D) to garner real-world experiences and their health outlook for the future following treatment with the first approved disease-modifying immune therapy for delaying the onset of Stage 3 T1D.

Materials and methods

This was a cross-sectional, observational, online survey (conducted September-October 2024) of adults (≥18 years) and caregivers of children (8-17 years) who received teplizumab while participating in the US COMPASS patient support program. Questions pertained to demographics, health history, T1D screening, the decision to take teplizumab, treatment, post-treatment experience, outlook on prognosis and self-reported health status. All data were summa

SUBMITTER: O'Donnell HK 

PROVIDER: S-EPMC11965029 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature